ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions
Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
  • Abstract Number: 0914
    RAB19 and Azathioprine-Associated Pancreatic Injury in Patients Taking Azathioprine
  • Abstract Number: 2313
    Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis
  • Abstract Number: 0176
    Race-Based Differences in Immune Responses Following an Episode of Acute Low Back Pain Among Those Who Develop Chronic LBP and Those Who Do Not
  • Abstract Number: 2017
    Race, Ethnicity, and Rheumatology Care Predict Long-term Urate-Lowering Treatment Persistence Following a Treat-to-Target Intervention in a Large, Multicenter Randomized Trial
  • Abstract Number: 1873
    Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality
  • Abstract Number: 1926
    Race/ethnicity Is Associated with Disease Severity in Pediatric Patients with ANCA-associated Vasculitis Hospitalized in the United States
  • Abstract Number: 1914
    Racial and Ethnic Differences in the Prevalence of Disease Features in Systemic Sclerosis
  • Abstract Number: 1924
    Racial and Gender Disparities in Psoriatic Arthritis Clinical Trials
  • Abstract Number: 0189
    Racial Discrimination Among African American Women with and Without Systemic Lupus Erythematosus (SLE)
  • Abstract Number: 1909
    Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study
  • Abstract Number: 0329
    Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores
  • Abstract Number: 2388
    Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
  • Abstract Number: 0792
    Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA
  • Abstract Number: 1450
    Radiographic Structural Spine Assessment in Ankylosing Spondylitis According to the Presence or Absence of Psoriasis
  • Abstract Number: 1973
    Radioisotopic Synoviorthesis: Factors Associated with Good Response Evaluated by Ultrasound
  • Abstract Number: 0959
    Radiomics Non-Invasively Conveys Time-Resolved Molecular Pathway Activity in Experimental Fibrosing Interstitial Lung Disease
  • Abstract Number: 1718
    Randomization to Holding versus Continuing (JAKi, IL17) and Autoimmune Patient Responses to COVID-19 Boosters: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study
  • Abstract Number: 1218
    Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia
  • Abstract Number: 2466
    Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease
  • Abstract Number: 1071
    Rapid Access Microscopy and Real Time Case Discussion via a Secure Messaging App Improves Diagnostic Accuracy and Management of Acute Hot Swollen Joints
  • Abstract Number: 1380
    Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib
  • Abstract Number: 0114
    Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
  • Abstract Number: 2646
    Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries
  • Abstract Number: 0814
    Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
  • Abstract Number: 1545
    Rates of Sustained Complete Renal Response with Long-term Use of Voclosporin in AURORA 2
  • Abstract Number: 0298
    RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults
  • Abstract Number: 2159
    Reaching Those in Need: Understanding the Reach of a Digital Program for Lupus Self-Management Education
  • Abstract Number: 0372
    Readability Analysis of the American College of Rheumatology Patient Education Material
  • Abstract Number: 1483
    Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
  • Abstract Number: 0586
    Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
  • Abstract Number: 0249
    Real World Evidence on the Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients with Rheumatic Diseases – Preliminary Results from a Prospective Multicenter Observational Greek Study
  • Abstract Number: 2674
    Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States
  • Abstract Number: 1627
    Real-World Data on Imaging Tests, Specifically Temporal Artery Ultrasound, in Giant Cell Arteritis in Japan: A Multicenter Retrospective Study
  • Abstract Number: 0508
    Real-World Evidence for GP2015 in Patients with Rheumatoid Arthritis: Safety Outcomes from German Observational Data
  • Abstract Number: 2284
    Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice
  • Abstract Number: 0594
    Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review
  • Abstract Number: 0168
    Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database
  • Abstract Number: 1495
    Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
  • Abstract Number: 0299
    Real-World Tolerability of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease
  • Abstract Number: 1456
    Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort
  • Abstract Number: 0214
    Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheumatoid Arthritis-Associated Interstitial Lung Disease
  • Abstract Number: 2484
    Real-World Use of Avacopan for ANCA-Associated Vasculitis Beyond 52 Weeks
  • Abstract Number: 0248
    Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study
  • Abstract Number: 1721
    Recombinant Zoster Vaccine Uptake in US Adults with Rheumatic Disease: A Mixed Methods Analysis
  • Abstract Number: 1037
    Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review
  • Abstract Number: 1899
    Recurrent Heart Failure Hospitalization in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study
  • Abstract Number: 2370
    Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus
  • Abstract Number: 0910
    Reduced Adenosine-Mediated Regulatory Activity Exacerbated by an NT5E Loss of Function Mutation Is Linked to Tissue Inflammation and Hypertension in Systemic Lupus Erythematosus
  • Abstract Number: 1157
    Reduced Statin Use in Patients with Autoimmune Myopathies and Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Non-Inflammatory Diseases
  • Abstract Number: 1865
    Reduction in CD4+T Cell Expression of CD28 and CD2 by Antibody-induced Internalization of CD6: A Potential Step Towards Immune Tolerance
  • Abstract Number: 1764
    Reduction in Circulating Neutrophil Extracellular Traps and Restored Degradation Post-treatment in Pediatric Lupus
  • Abstract Number: 2438
    Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus
  • Abstract Number: 1936
    Referral and Diagnostic Delays of Patients with Chronic Inflammatory Rheumatic Diseases: A Cross-sectional Study in Eight Countries
  • Abstract Number: 0033
    Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles
  • Abstract Number: 0115
    Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry
  • Abstract Number: 0757
    Regulation of Macrophage Differentiation by Serum Adiponectin: A Novel Mechanism to Increase Alternatively Activated Macrophages During the Remission Phase of Giant Cell Arteritis
  • Abstract Number: 2236
    Relation Between Sociodemographic Factors and Hand Function in Patients with Early Rheumatoid Arthritis
  • Abstract Number: 1196
    Relation of Different Types of Antidepressants Use to Pain Severity and Measures of Pain Sensitization in Kneeosteoarthritis
  • Abstract Number: 1180
    Relationship Between Changes in Physical Activity and Early Onset Knee Osteoarthritis in Individuals After ACL Reconstruction
  • Abstract Number: 0414
    Relationship Between Culture Negative Infectious Osteomyelitis and Chronic Nonbacterial Osteomyelitis
  • Abstract Number: 1442
    Relationship Between Degenerative Lesions over Time in Axial Spondyloarthritis: 10-year Follow-up of the DESIR Cohort
  • Abstract Number: 1393
    Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials
  • Abstract Number: 2007
    Relationship Between Gout Flare Burden and Patient-Reported Outcome Following Allopurinol Initiation
  • Abstract Number: 1192
    Relationship Between Measures of Fat Mass and Knee Osteoarthritis Incidence: The Multicenter Osteoarthritis (MOST) Study
  • Abstract Number: 1133
    Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators
  • Abstract Number: 0655
    Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry
  • Abstract Number: 1350
    Relationship Between Salivary and Stool Microbiome with Disease Activity and Vascular Function in Patients with Rheumatoid Arthritis
  • Abstract Number: 2559
    Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis
  • Abstract Number: 2127
    Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population
  • Abstract Number: 2230
    Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis
  • Abstract Number: 0497
    Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis
  • Abstract Number: 2092
    Remote-Delivered Tai Chi and Gut Microbiota in Osteoarthritis: A Randomized Mechanistic Trial
  • Abstract Number: 0651
    Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis
  • Abstract Number: 2364
    Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
  • Abstract Number: 0402
    Reporting of Clinical Features and Outcome Measures in Still’s Disease: A Systematic Literature Review of sJIA and AOSD Cohorts
  • Abstract Number: 1680
    Reporting Quality of Non-inferiority and Equivalence Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review
  • Abstract Number: 2600
    Repression of the Aryl-hydrocarbon Receptor Prevents Oxidative Stress and Ferroptosis of Intestinal γδT Cells and Alleviates Systemic Lupus Erythematosus
  • Abstract Number: 0885
    Reproducible Single Cell Annotation of Programs Underlying T-cell Subsets, Activation States, and Functions
  • Abstract Number: 0431
    Reproductive Health in Women with Rheumatic Diseases: Knowledge and Behaviors
  • Abstract Number: 0452
    Reproductive Health Needs of Women with Rheumatic Disease: An EMR-Based Online Survey Study
  • Abstract Number: 0358
    Residual’ Fatigue and Its Severity in Patients with Rheumatoid Arthritis in Clinical Remission: Prevalence and Associated Factors
  • Abstract Number: 1790
    Response Gene to Complement-32 Expression Is Upregulated in Lupus T Cells and Promotes Th17 Differentiation
  • Abstract Number: 1594
    Response to Mepolizumab Therapy in a Single-center Cohort of Eosinophilic Granulomatosis with Polyangiitis Patients: Characterization of Cytokine/Chemokine Pattern and Phenotypic Stratification
  • Abstract Number: 0682
    Results from Outcomes Selection and Development of a Patient-reported Outcome Measure for a Combined Response Index for Limited Cutaneous SSc: The CRISTAL Project
  • Abstract Number: 2586
    Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
  • Abstract Number: 0805
    Results from the Certolizumab-pegol Pregnancy Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project
  • Abstract Number: 1697
    Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Methotrexate 25mg Per Week for Recently Diagnosed PolyMyalgia Rheumatica
  • Abstract Number: 1501
    Retrospective Cohort Study Identifying Pulmonary Complications in a Cohort of Patients with Systemic Lupus Erythematosus
  • Abstract Number: PP05
    Reunion with Forgotten Relationships and Memories
  • Abstract Number: 0947
    REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis
  • Abstract Number: 0446
    Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications
  • Abstract Number: 2122
    Rheum for Improvement: Screening and Treatment of Glucocorticoid Induced Osteoporosis
  • Abstract Number: 1235
    Rheum to Grow: Supporting Young Adults with Childhood-Onset Rheumatic Disease in Their Transition to Adult Care
  • Abstract Number: 2004
    Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
  • Abstract Number: 1115
    Rheumatic Disease Patients: Assessment of Hydroxychloroquine’s Effects on QTc Intervals with Weight Based Dosing (RAISE-QT) Study
  • Abstract Number: 0254
    Rheumatic Manifestations in Patients with Hansen’s Disease Treated with Multidrug Antibiotic Therapy
  • Abstract Number: 0475
    Rheumatoid Arthritis – Progressive Interstitial Lung Disease with Abatacept: Data from a Large National Multicenter Cohort
  • Abstract Number: 1324
    Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations
  • Abstract Number: 0135
    Rheumatoid Arthritis Associated Risk of Venous Thromboembolism Is Not Dependent on Disease Duration: United Kingdom Based Population Study
  • Abstract Number: 1661
    Rheumatoid Arthritis Synovial Fibroblast Modulation of T Cell Activation
  • Abstract Number: 0158
    Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023
  • Abstract Number: 2149
    Rheumatoid Arthritis: Patient’s Voice First! An Original Approach Based on Infodemiology Using Social Media Content – Results from the PRIMA Study
  • Abstract Number: 0777
    Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients
  • Abstract Number: L11
    Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
  • Abstract Number: 2151
    Rheumatology on Reddit: A Descriptive Analysis
  • Abstract Number: 0210
    Rheumatology, Heal Thyself: The Experience of Underrepresented Physicians in Rheumatology
  • Abstract Number: 1252
    Rheuminating About Drugs, Sex, and Alcohol? Assessing the Informational Needs of Adolescents and Young Adults with Rheumatic Disease
  • Abstract Number: 1737
    RheumMadness 2024: The Practical Impact of the Practically Perfect Season
  • Abstract Number: 1644
    RISE Registry Associated with Significant Gains in Quality Measure Performance: An InterruptedTimes Series Analysis Before and After Participation
  • Abstract Number: 1086
    Risk Factors Associated with Loss to Follow-up in a Prospective Gout Cohort
  • Abstract Number: 0527
    Risk Factors for Leukopenia in Asian Patients with Rheumatoid Arthritis Undergoing Tocilizumab
  • Abstract Number: 2458
    Risk Factors for Progression of Interstitial Lung Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis
  • Abstract Number: 2693
    Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
  • Abstract Number: 0453
    Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family
  • Abstract Number: 2631
    Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study
  • Abstract Number: 2261
    Risk of Cervical Intraepithelial Neoplasia During Janus Kinase (JAK) Inhibitor Treatment in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
  • Abstract Number: 1093
    Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias
  • Abstract Number: 2579
    Risk of End-Stage Renal Disease Among Patients with Lupus Nephritis on GLP-1 Receptor Agonists: A Retrospective Cohort Study
  • Abstract Number: 1439
    Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class
  • Abstract Number: 2009
    Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes
  • Abstract Number: 1336
    Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
  • Abstract Number: 1401
    Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
  • Abstract Number: 1102
    Risk of Mortality and Major Cardiovascular-Kidney Outcomes in Patients with Tophaceous versus Non-Tophaceous Gout
  • Abstract Number: 2614
    Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis
  • Abstract Number: 1127
    Risk of Ocular Inflammatory Conditions in Patients with Autoimmune Diseases: A Retrospective Study Using the National Inpatient Sample
  • Abstract Number: 0719
    Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease
  • Abstract Number: 1867
    RNA Polymerase III Specific CD8+ T Cells at the Interface Between Scleroderma and Cancer
  • Abstract Number: 0969
    Role and Mechanism of the Wnt3a-FZD5 Pathway in Regulating the Transformed Intermediate State of Alveolar Epithelial Cells Involved in Pulmonary Fibrosis in Systemic Sclerosis
  • Abstract Number: 2225
    Role of Fatigue in Difficult to Treat Rheumatoid Arthritis
  • Abstract Number: 2131
    Role of LECT2 in the Regulation of Bone Metabolism In Vitro and In Vivo
  • Abstract Number: 1831
    Role of Long Non-Coding RNA H19 in Mediating Skin Fibrosis in Systemic Sclerosis
  • Abstract Number: 0917
    Role of Mutual Information Profile Shifts in Assessing the Pathogenicity of Mutations on Protein Functions: The Case of Pyrin Mutations in Familial Mediterranean Fever
  • Abstract Number: 1238
    Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica
  • Abstract Number: 2052
    Role of Scleroderma/myositis-related Autoantibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 410 Patients from a Single Referral Center
  • Abstract Number: 0048
    Role of the Chemokine CCL22 in Rheumatoid Arthritis Development
  • Abstract Number: 0806
    Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events
  • Abstract Number: 0784
    RUNX1 Is Expressed in a Subpopulation of Dermal Fibroblasts and Is Increased with Systemic Sclerosis Disease Severity
  • Abstract Number: 1014
    Rural-dwelling Patients with Rheumatoid Arthritis or Those with Lower Income Are More Likely to Be Admitted for Myocardial Infarction in the U.S. and Have Worse Outcomes
  • Abstract Number: 0177
    Rural-urban Disparities in the Myocardial Infarction Hospitalizations in People with Systemic Lupus Erythematosus in the US
  • Abstract Number: 0737
    Rurality and Delayed Diagnosis of Giant Cell Arteritis – a Single Center Experience
Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology